1 / 65

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005. LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA. GIOVANNI MANTOVANI CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA’ DEGLI STUDI DI CAGLIARI.

manton
Download Presentation

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA GIOVANNI MANTOVANI CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA’ DEGLI STUDI DI CAGLIARI

  2. THE MOLECULARLY TARGETED ANTICANCER TREATMENT • The so-called molecularly targeted anticancer treatment is based on compounds that interefere with cell targets directly connected with pathogenetic events. Such therapies are expected to target specifically tumor cells, thus allowing for strong anticancer effects and minimal toxicities

  3. The possible targets are represented by: • the interaction between the ligand (growth factor) and its specific receptor with the consequent activation of a cascade of biochemical events leading to the transduction of the cell proliferating signal from the membrane surface to the nucleus; • the cell cycle checkpoint, acting by a negative counterregulation • the apoptosis, by using proapoptotic molecules

  4. (neo)angiogenesisthrough angiogenesis inhibitors • the immune compartment of the host, by modulating his immune response

  5. EGFR INHIBITION (Harari PM, Huang SM. Clin Can Res 10:428, 2004)

  6. * *HRPC: hormone-refractory prostate cancer

More Related